Publication

Article

BioPharm International

BioPharm International-09-15-2017
Volume2017 eBook
Issue 2
Pages: 4-9

Overcoming Hurdles in Emerging Therapy Development

Author(s):

The development of emerging therapies poses unique manufacturing and formulation challenges for drug developers as candidates like cell and gene therapies advance through the pipeline.

As precision medicines garner increasing attention, drug makers have intensified their efforts to bring emerging therapies such as cell and gene therapies to market. This article gives an overview of cell/gene therapies in the making and explores the challenges biomanufacturers face in developing and manufacturing such inherently complex molecules. Unlike traditional small-molecule drugs and conventional antibody-based biologics, the roadblocks to developing and manufacturing cell and gene therapies can get complicated because of their molecular complexity and the fact that their mechanisms of action are not fully understood.

Download the

BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook

.

 

Article Details

BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 4-9

Citation

When referring to this article, please cite it as F. Mirasol, "Overcoming Hurdles in Emerging Therapy Development, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
© 2025 MJH Life Sciences

All rights reserved.